Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.54 |
| ▸ | EGFR | P00533 | 7/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 9/20 | 0.52 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.52 |
| ▸ | TUBB | P07437 | 5/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.52 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.52 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114812 | 0.81 | KDR (0.66) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL23077791 | 0.81 | KDR (0.66) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL4845879 | 0.75 | KDR (0.62) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL18540821 | 0.72 | KDR (0.58) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL17528563 | 0.72 | KDR (0.58) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL17528560 | 0.72 | KDR (0.58) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL17528561 | 0.71 | KDR (0.53) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL17528559 | 0.70 | KDR (0.56) | KDREGFRPDGFRBTUBB3TUBB4A | |
| Verubulin SCHEMBL29379614 | 0.70 | KDR (1.00) | KDREGFRPDGFRBTUBB3TUBB4A | |
| SCHEMBL17528562 | 0.70 | KDR (0.59) | KDREGFRPDGFRBTUBB3TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-14 | — | — | US | claimed |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-07 | — | — | US | claimed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | KDR 3722/4885EGFR 3147/4885PDGFRB 2783/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20080032974-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | KDR 3716/4885EGFR 2915/4885PDGFRB 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.